Weiyun Z. Ai - Concepedia

Author

Weiyun Z. Ai

University of California, San Francisco ORCID

Also Known As

Horwitz, Mitchell E., Manyam, Ganiraju C., W Z Ai, W. Ai, W. Z Ai, W. Z. Ai, Weijie Ai, Weiyun Ai, Weiyun Z Ai, Weiyun Z. Ai

181

Publications

Citations

H-Index

Concepts

All Affiliations

University of California, San Francisco The University of Texas MD Anderson Cancer Center UCSF Helen Diller Family Comprehensive Cancer Center Memorial Sloan Kettering Cancer Center Cleveland Clinic

About

Weiyun Z. Ai is an author at University of California, San Francisco specializing in medicine, pathology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	21	1.6K
2	Health Sciences	3	3	36
3	Blood Transplantation	3	3	49
4	Cell Biology	3	3	57
5	Allergy	1	1	24

Weiyun Z. Ai

Publications

4.7K

Citations

H-Index

Page 1

	Year	Citations
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program Shimin Hu, Zijun Y. Xu‐Monette, Alexandar Tzankov, Blood	2013	671
In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study Joshua Brody, Weiyun Z. Ai, Debra K. Czerwinski, Journal of Clinical Oncology	2010	482
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial Paolo F. Caimi, Weiyun Z. Ai, Juan Pablo Alderuccio, The Lancet Oncology Loncastuximab TesirineLymphoid NeoplasiaHematological MalignancyMedicineImmunology	2021	397
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study Zijun Y. Xu‐Monette, Lin Wu, Carlo Visco, Blood	2012	383
CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study Shimin Hu, Zijun Y. Xu‐Monette, Aarthi Balasubramanyam, Blood	2013	243
In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study Youn H. Kim, Dita Gratzinger, Cameron Harrison, Blood ImmunologyImmunoeditingPathologyImmunotherapyLocal Radiation	2011	211
Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study Carlo Visco, Alexandar Tzankov, Zijun Y. Xu‐Monette, Haematologica	2012	165
T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology Steven M. Horwitz, Stephen M. Ansell, Weiyun Z. Ai, Journal of the National Comprehensive Cancer Network	2022	153
Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology Richard T. Hoppe, Ranjana H. Advani, Weiyun Z. Ai, Journal of the National Comprehensive Cancer Network Lymphoid NeoplasiaHodgkin LymphomaMedicineCancer ManagementMalignant Blood Disorder	2020	148
Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology Richard T. Hoppe, Ranjana H. Advani, Weiyun Z. Ai, Journal of the National Comprehensive Cancer Network Lymphoid NeoplasiaHodgkin LymphomaMedicineCancer ManagementTreatment Response	2017	140

Page 1